2023
Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma. International Journal Of Molecular Sciences 2023, 24: 4748. PMID: 36902188, PMCID: PMC10003180, DOI: 10.3390/ijms24054748.Peer-Reviewed Original ResearchConceptsMetS patientsMetabolic syndromeNon-alcoholic fatty liver disease/non-alcoholic steatohepatitisNon-alcoholic steatohepatitisIntrahepatic cholangiocarcinoma developmentPutative therapeutic targetDeposition of osteopontinCell-like phenotypeBiliary tumorigenesisExtracellular matrix depositionVascular complicationsSurgical resectionIntrahepatic cholangiocarcinomaICCA cellsOverexpression of osteopontinPredictive biomarkersLiver tumorsCommon conditionHuCCT-1Tumor stromaCholangiocarcinoma developmentPeritumoral areaTherapeutic targetBiliary differentiationOsteopontin overexpression
2018
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C, Association A. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.Peer-Reviewed Original ResearchConceptsHepatitis C virusNon-alcoholic steatohepatitisHepatitis B virusEuropean Liver Transplant RegistryLiver transplantationSurvival of recipientsDAA eraLiver diseaseHepatocellular carcinomaEvolution of indicationsVirus infectionNumber of LTsHepatitis B virus infectionHepatitis C virus infectionAdult liver transplantationAdvent of DAAsImpact of DAAsLiver Transplant RegistrySecond-generation DAAsC virus infectionLiver transplant recipientsOutcomes of patientsB virus infectionThree-year survivalDAA treatment